AJPC Publishes First Study Under New Editor Revealing Sex Differences in Rare Cholesterol Disorder

  • The American Journal of Preventive Cardiology (AJPC) published a landmark study on sex differences in homozygous familial hypercholesterolemia (HoFH) under new Editor-in-Chief Dr. Khurram Nasir.
  • The multinational study found baseline LDL-C levels were significantly higher in females than males with HoFH, a previously unreported observation.
  • Treatment with evinacumab, an ANGPTL-3 inhibitor developed by Regeneron Pharmaceuticals, reduced LDL-C levels in both sexes over 24 weeks.
  • An accompanying editorial called for greater inclusion of women in cardiovascular clinical trials.

This study highlights the growing emphasis on sex-specific data in medical research, particularly in rare genetic conditions. The publication under AJPC's new leadership signals a strategic focus on inclusive, high-impact preventive cardiology science. The findings could influence both clinical practice and regulatory standards for managing HoFH.

Research Impact
How these findings will influence future clinical trials and treatment protocols for HoFH patients.
Editorial Direction
Whether Dr. Nasir's leadership will continue to prioritize sex-specific analyses in preventive cardiology research.
Regulatory Influence
The pace at which regulatory bodies may incorporate these findings into guidelines for cardiovascular disease management.